Cost analysis with censored data.

Economic evaluation of medical interventions has become an accepted, and often required, adjunct to the standard effectiveness and safety assessment in clinical research. However, the statistical analysis can be challenging due to censored cost data, as commonly obtained in medical studies. Over the past decade, important statistical issues that arise from censored cost data have been identified and a number of advances made to tackle them. In this article, we will describe these issues, including induced dependent censoring and limited identifiability with the cost distribution, and review recent statistical developments. Available methods address either time-restricted medical cost or lifetime medical cost jointly with survival time. Their applicability and limitation in various practical situations will be discussed.

[1]  B. O'brien Outcomes Assessment in Cancer: Cost-effectiveness analysis in cancer: toward an iterative framework for integration of evidence from trials and models , 2004 .

[2]  E. Feuer,et al.  Estimating medical costs from incomplete follow-up data. , 1997, Biometrics.

[3]  Thomas A. Louis,et al.  Nonparametric estimation of the joint distribution of survival time and mark variables , 1998 .

[4]  D. Horvitz,et al.  A Generalization of Sampling Without Replacement from a Finite Universe , 1952 .

[5]  J. Robins,et al.  Recovery of Information and Adjustment for Dependent Censoring Using Surrogate Markers , 1992 .

[6]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[7]  Anastasios A. Tsiatis,et al.  Estimating medical costs with censored data , 2000 .

[8]  Nicholas P. Jewell,et al.  AIDS epidemiology : methodological issues , 1993 .

[9]  H Zhao,et al.  On Estimating Medical Cost and Incremental Cost‐Effectiveness Ratios with Censored Data , 2001, Biometrics.

[10]  Anastasios A Tsiatis,et al.  Median Regression with Censored Cost Data , 2002, Biometrics.

[11]  D. Lin,et al.  Regression analysis of incomplete medical cost data , 2003, Statistics in medicine.

[12]  Robert L. Strawderman,et al.  Estimating the Mean of an Increasing Stochastic Process at a Censored Stopping Time , 2000 .

[13]  J. Crowley,et al.  Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. , 2002, Journal of the National Cancer Institute.

[14]  P Fenn,et al.  The Analysis of Censored Treatment Cost Data in Economic Evaluation , 1995, Medical care.

[15]  H. Bang Medical cost analysis: application to colorectal cancer data from the SEER Medicare database. , 2005, Contemporary clinical trials.

[16]  J. Robins,et al.  Estimation of Regression Coefficients When Some Regressors are not Always Observed , 1994 .

[17]  B. Efron The two sample problem with censored data , 1967 .

[18]  Hongwei Zhao,et al.  On the equivalence of some medical cost estimators with censored data. , 2007, Statistics in medicine.

[19]  TESTS FOR LIFETIME UTILITY OR COST VIA CALIBRATING SURVIVAL TIME , 2002 .

[20]  J Lipscomb,et al.  The burden of illness of cancer: economic cost and quality of life. , 2001, Annual review of public health.

[21]  J. Crowley,et al.  Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Lin,et al.  Linear regression analysis of censored medical costs. , 2000, Biostatistics.

[23]  Yijian Huang,et al.  Calibration Regression of Censored Lifetime Medical Cost , 2002 .